drugset / Trial / NCT01083264

Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites

NCT01083264

Phase 1 Completed 43 enrolled Bayer
RandomizedCrossoverOpen-labelTreatment

Summary

Influence of different application sites on the blood levels after administration of a fertility control patch

Timeline

Start
2009-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Gestodene Small molecule 2.1 mg Other
Subject ethinyl estradiol Small molecule 0.55 mg Other

Indications

No indication recorded.